Hints and tips:
...But they warn that the ruling casts a shadow over the company as it seeks to remodel itself as an innovator in the pharmaceutical and medical devices sectors....
...Others stand by the name, though — defending it as a way to differentiate their role as a protector and an ethical voice within the business....
...Before the pandemic, Ackman was best known for a quixotic and bitter campaign against Herbalife, a purveyor of health supplements he accused of being a covert pyramid scheme....
...Regeneron, though, is hardly a mom-and-pop business. It has a market value of $60bn....
...The generics division has long weighed on profitability. For 2020, the unit’s operating profit margins were 11 per cent — half those of the innovative medicines division....
...J&J is following a trend in the pharmaceutical sector, as companies dispose of slower growing consumer healthcare divisions to concentrate on drug discovery....
...McKinney added that it would be difficult for J&J to show the adenovirus method “is as good as doing it directly with lipid droplets like Moderna and Pfizer are using in their coronavirus vaccines”....
...Yet by 2005, when Rahul Singhvi took over as chief executive, the women’s health business was being derailed by competition and concerns that oestrogen treatments increased the risk of breast cancer....
...“It would be stupidity on steroids if Congress left for Christmas without doing an interim package as a bridge [to the next administration],” said Mark Warner, the Virginia Democrat and one of the sponsors...
...The settlement with Sandoz does not require the company to plead guilty to a criminal charge, which has long been the practice of the antitrust division, but instead allows the business to enter into a three-year...
...As well as women’s health, it will sell branded drugs in dermatology, pain and respiratory diseases, as well as biosimilars, which are generic versions of biologic medicines....
...Democrats and Republicans have condemned the wider pharmaceutical industry for soaring drug prices, and some have pointed to pay packages, like the $25m Mr Gorsky made in 2019, as a part of the problem....
...But she hopes the sheer fact of people going to prison will deter other drugmakers, which may have previously accepted fines as a cost of doing business....
...a pool of talented women to become future leaders for EBA,” he wrote....
...“As a result, different samples may provide different results....
...According to Japan’s Fermata Inc, which provides services to femtech start-ups, there were 318 companies focused on women’s health worldwide in March 2020, up from 221 in 2019 and 50 in 2017....
...The combined business is expected to generate revenues of $19bn to $20bn, putting it just ahead of Israeli drugmaker Teva, and adjusted earnings of between $7.5bn and $8bn a year....
...“From a public health perspective, criminal charges are important because a fine can be seen by a company as a cost of doing business,” he said....
...the consumer health business into a joint venture with US rival Pfizer?...
...Johnson & Johnson, the world’s largest healthcare group, hailed a strong performance in its pharmaceuticals unit as it unveiled second-quarter earnings that were ahead of Wall Street expectations....
...Pfizer recently tried and failed to sell its own consumer health division. Despite emerging from the consumer health division, Ms Walmsley is probably not as wedded to it as her predecessor....
...2018 Nikkei Inc....
...A CVS-Aetna deal would combine the third largest health insurer in the US with the two planks of CVS’s business: a pharmacy benefits manager (PBM) that negotiates the prices of medicines with pharma groups...
...Mr Fernandez predicts investors will intensify calls for the women’s health division to be sold or spun off....
...I think that means it will be a big year for Chinese companies doing overseas deals.”...
International Edition